Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kolon/Mitsubishi Gene Therapy Pact Paves Way For More Global Deals?

Executive Summary

In a rare large gene therapy deal, South Korea’s Kolon is making inroads into the Japanese market through Invossa, its genetically modified allogeneic cell therapy for osteoarthritis. The agreement with Mitsubishi Tanabe could pave the way for more global licensing agreements in a growing segment.

You may also be interested in...



Kolon Bounces Back From Failed Japan Invossa Deal With Bigger Mundipharma Alliance

Kolon Life Science has reached a sizable license deal with Mundipharma for the development in Japan of the South Korean company’s first-in-class cell and gene therapy for osteoarthritis of the knee, easing uncertainties after an agreement with Mitsubishi Tanabe for the product collapsed last year.

Spotlight On TissueGene’s Upcoming Korea IPO

Regenerative drug company TissueGene’s proposed IPO in South Korea is drawing keen interest, coming close on the heels of the recent approval of its novel osteoarthritis drug in the country. Success of the IPO will be crucial for the company to proceed with a Phase III US study of the drug.

First Approval For Kolon's Invossa But No Disease-Modifying Status

Kolon Life Science's Invossa gets regulatory approval in South Korea as the world's first allogeneic cell-mediated gene therapy for degenerative osteoarthritis, but misses out on disease-modifying status, although the company hopes a large-scale Phase III study can rectify this in the US.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1128165

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel